Claims
- 1. An isolated nucleic acid molecule encoding a recombinant HCV genome, comprising the nucleotide sequence of FCA1 (SEQ ID NO: 15).
- 2. A stable cell line transfected with the isolated nucleic acid molecule of claim 1, wherein said cell line is capable of supporting efficient replication of said isolated nucleic acid.
- 3. The cell line of claim 2, wherein said cell line is selected from the group consisting of human hepatoma cell line Huh-7, human hepatoma cell line HepG2, hepatoma cell line PH5CH, T. belangeri liver cell line MBTL, human diploid fibroblast cell line VERO, secondary monkey kidney cell line CV-1, T cell line MT-2, T cell line HPBMa10-2, T cell line MOLT-4, and B cell line Daudi.
- 4. The cell line of claim 3, wherein said cell line is derived from human hepatoma cell line Huh-7.
- 5. The cell line of claim 4 designated FCA1 and having ATCC Accession No. ______.
- 6. An isolated nucleic acid molecule encoding a recombinant HCV genome, wherein said nucleic acid molecule comprises at least one consensus mutation of cell line FCA1.
- 7. A stable cell line transfected with the isolated nucleic acid molecule of claim 6, wherein said cell line is capable of supporting efficient replication of said isolated nucleic acid.
- 8. The isolated nucleic acid molecule of claim 6, wherein said nucleic acid molecule comprises a G to A mutation at position 1875.
- 9. The isolated nucleic acid molecule of claim 6, wherein said nucleic acid molecule comprises an A to G mutation at position 2330.
- 10. The isolated nucleic acid molecule of claim 6, wherein said nucleic acid molecule comprises a C to G mutation at position 5487.
- 11. The isolated nucleic acid molecule of claim 6, wherein said nucleic acid molecule comprises an A to G mutation at position 5695.
- 12. An isolated nucleic acid molecule encoding a recombinant HCV genome, comprising the nucleotide sequence of FCA4 (SEQ ID NO: 16).
- 13. A stable cell line transfected with the isolated nucleic acid molecule of claim 12, wherein said cell line is capable of supporting efficient replication of said isolated nucleic acid.
- 14. The cell line of claim 13, wherein said cell line is selected from the group consisting of human hepatoma cell line Huh-7, human hepatoma cell line HepG2, hepatoma cell line PH5CH, T. belangeri liver cell line MBTL, human diploid fibroblast cell line VERO, secondary monkey kidney cell line CV-1, T cell line MT-2, T cell line HPBMa10-2, T cell line MOLT-4, and B cell line Daudi.
- 15. The cell line of claim 14, wherein said cell line is derived from human hepatoma cell line Huh-7.
- 16. The cell line of claim 15 designated FCA4 and having ATCC Accession No. ______.
- 17. An isolated nucleic acid molecule encoding a recombinant HCV genome, wherein said nucleic acid molecule comprises at least one consensus mutation of cell line FCA4.
- 18. The isolated nucleic acid molecule of claim 17, wherein said nucleic acid molecule comprises a deletion of nucleotides 5327-5329.
- 19. A stable cell line transfected with the isolated nucleic acid molecule of claim 18, wherein said cell line is capable of supporting efficient replication of said isolated nucleic acid.
- 20. The cell line of claim 19, wherein said cell line is selected from the group consisting of human hepatoma cell line Huh-7, human hepatoma cell line HepG2, hepatoma cell line PH5CH, T. belangeri liver cell line MBTL, human diploid fibroblast cell line VERO, secondary monkey kidney cell line CV-1, T cell line MT-2, T cell line HPBMa10-2, T cell line MOLT-4, and B cell line Daudi.
- 21. The cell line of claim 20, wherein said cell line is derived from human hepatoma cell line Huh-7.
- 22. An isolated nucleic acid molecule encoding a recombinant HCV genome, comprising the nucleotide sequence of FCA22 (SEQ ID NO: 17).
- 23. A stable cell line transfected with the isolated nucleic acid molecule of claim 22, wherein said cell line is capable of supporting efficient replication of said isolated nucleic acid.
- 24. The cell line of claim 23, wherein said cell line is selected from the group consisting of human hepatoma cell line Huh-7, human hepatoma cell line HepG2, hepatoma cell line PH5CH, T. belangeri liver cell line MBTL, human diploid fibroblast cell line VERO, secondary monkey kidney cell line CV-1, T cell line MT-2, T cell line HPBMa10-2, T cell line MOLT-4, and B cell line Daudi.
- 25. The cell line of claim 24, wherein said cell line is derived from human hepatoma cell line Huh-7.
- 26. The cell line of claim 26 designated FCA22 and having ATCC Accession No. ______.
- 27. An isolated nucleic acid molecule encoding a recombinant HCV genome, wherein said nucleic acid molecule comprises at least one consensus mutation of cell line FCA22.
- 28. A stable cell line transfected with the isolated nucleic acid molecule of claim 27, wherein said cell line is capable of supporting efficient replication of said isolated nucleic acid.
- 29. The isolated nucleic acid molecule of claim 29, wherein said nucleic acid molecule comprises a T to C mutation at position 1777.
- 30. The isolated nucleic acid molecule of claim 29, wherein said nucleic acid molecule comprises a A to C mutation at position 4262.
- 31. The isolated nucleic acid molecule of claim 29, wherein said nucleic acid molecule comprises a C to T mutation at position 6881.
Parent Case Info
[0001] This application claims benefit of priority to U.S. application Ser. No. 10/005,469, entitled “Hepatitis C Virus Constructs Characterized by High Efficiency Replication” filed Nov. 7, 2001, and to U.S. Provisional Application No. 60/245,866 filed Nov. 7, 2000, both of which are hereby incorporated by reference in their entireties.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60245866 |
Nov 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10233307 |
Aug 2002 |
US |
Child |
10434842 |
May 2003 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10005469 |
Nov 2001 |
US |
Child |
10233307 |
Aug 2002 |
US |